SHINE believes that fusion will ultimately become humanity’s primary source of energy. However, reaching this point requires time, investment, and practical solutions. That is why SHINE has adopted a scalable approach that addresses critical challenges at every stage, designing and operating innovative fusion systems for short-term applications such as medical isotope production and advanced material testing. These steps are laying the solid foundation for a future powered by fusion energy.

What truly differentiates SHINE from other fusion companies is that it has already commercialized fusion today and begun scaling its technology. Across its four-phase roadmap, SHINE continues to perfect the essential competencies for commercially viable fusion, deliver valuable products, create sustainable shareholder value, and invest in long-term growth.

As Nukleon, we are proud to serve as the authorized distributor of the NCA (NON CARRIER ADDED) LUTETIUM-177 (Lu-177) – ILUMIRA product of SHINE in the Turkish market.

For more information, you can visit the link www.shinefusion.com.